Detailed explanation of the correct method and dosage of capmatinib

Capmatinib (Capmatinib) is a targeted therapy drug for non-small cell lung cancer (NSCLC) caused by MET gene mutations. Its administration method and dosage are crucial to the therapeutic effect. Although the specific dosage regimen needs to be determined based on the patient's actual condition and the doctor's professional advice, the following will provide general dosage guidelines and recommended dosages so that patients can better understand and follow medical advice.

1. How to take

Capmatinib is usually given to patients as an oral tablet. To ensure adequate absorption of the drug, patients are advised to take capmatinib with a meal. This is important because food can help increase the bioavailability of medications. When taking the tablet, the patient should swallow the tablet whole and do not chew or crush it to avoid affecting the release and absorption of the drug.

If the patient misses a dose for any reason, there is no need to take double the next dose. Missing a dose usually does not have a significant impact on treatment, and patients should continue to take their next dose on their normal schedule. However, if the missed dose lasts for a long time or the patient has concerns about it, it is recommended to consult a doctor in time to obtain professional treatment advice.

2. Recommended dosage

The recommended starting dose of capmatinib is 400mg twice daily. Patients should strictly follow this dose until unacceptable side effects occur or the doctor adjusts the dose based on clinical conditions. The doctor will adjust the drug dose in a timely manner based on the patient's tolerance and treatment response to achieve the best therapeutic effect.

During treatment, patients undergo regular clinical examinations and laboratory tests to evaluate the efficacy of the drug and monitor possible side effects. Based on the test results, the doctor may adjust the treatment plan, including stopping treatment or adjusting the dosage of medication.

3. Be wary of drug interactions

Capmatinib may interact with other medications, affecting their efficacy or increasing the risk of side effects. Therefore, before starting capmatinib, patients must inform their doctor about all medications they are taking, including prescription, over-the-counter, and herbal medicines. This is especially true of drugs that may affect liver enzyme activity, as they may alter the rate of capmatinib metabolism, leading to fluctuations in drug concentrations.

4. Precautions during use

1. Liver function monitoring: Capmatinib may have an impact on liver function, so liver function indicators need to be checked regularly during use. If abnormal liver function is found, the doctor may adjust the dose of the drug or suspend treatment.

2. Contraindicated during pregnancy and lactation: Capmatinib may cause harm to the fetus, so pregnant women should avoid using this drug. At the same time, the safety of capmatinib in lactating women has not yet been clarified, so lactating women should also avoid using it.

3. Pulmonary function monitoring: Capmatinib may cause pulmonary complications, such as shortness of breath, cough and other symptoms. Patients should pay close attention to respiratory symptoms during treatment and seek medical examination in time.

4. Individualized treatment: The dose of capmatinib should be adjusted individually based on the patient's physical condition, tolerance and occurrence of side effects. All dosage adjustments should be made under the guidance of a professional physician to ensure the safety and effectiveness of treatment.

In short, capmatinib is an effective treatment for non-small cell lung cancer with MET gene mutations. Patients should strictly follow the doctor's prescription instructions during use, take the medicine on time and in the right amount, and pay close attention to possible side effects and adverse reactions. At the same time, regular clinical examinations and laboratory tests are also important to ensure the effectiveness and safety of treatment.

xa0

Reference materials

1.Official website of Novartis:https://www.novartis.com

2.United StatesFDAInstructions on capmatinib:https://www.fda.gov